Secteurs & marchés
NUS Medicine and Cyclotek strengthen Singapore’s radiopharmaceutical ecosystem
PHOTO: NUS Singapore
Market Info | Health & Lifestyle | Pharmaceuticals and Biotech
Date: 15 January 2026
Region: ASEAN-O
Country: Singapore
Sector: Health & Lifestyle
Sub-sector: Pharmaceuticals and Biotech
Section: Market Trends
Theme: Medical innovation and clinical research
The Clinical Imaging Research Centre (CIRC) at NUS Medicine has announced a strategic partnership with Cyclotek aimed at strengthening Singapore’s capabilities in the development, production, and distribution of radiopharmaceuticals. This collaboration covers the entire value chain, from advanced molecular imaging research to clinical trials and industrial supply, with the objective of accelerating access to innovative targeted diagnostics and therapies.
The initiative comes at a time of rapid growth in precision medicine across Asia, particularly in oncology, where radiopharmaceuticals play a central role in early diagnosis, therapeutic monitoring, and the optimization of personalized treatments. CIRC contributes its expertise in translational research, biomarker development, and clinical trials, while Cyclotek brings its industrial production capabilities, compliance with international standards, and specialized logistics network.
This collaboration will help secure local and regional supply of radiopharmaceuticals while reducing delays associated with importing short half-life products. It also aims to support the development of new imaging and therapeutic agents, from preclinical stages through to clinical use, thereby strengthening Singapore’s medical research ecosystem.
The project further provides for the harmonization of clinical protocols and imaging practices, facilitating data sharing and collaboration among hospitals, researchers, and industry stakeholders. This standardization is expected to improve the quality of clinical trials and accelerate the translation of innovation into medical practice.
Beyond its medical benefits, this partnership illustrates Singapore’s strategy to consolidate its position as a regional biomedical sciences hub. By fostering public-private collaboration and attracting specialized international players, Singapore enhances its attractiveness for investment in clinical research, advanced health technologies, and biomedical innovation across ASEAN.
